Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of VERT-002 in MET-altered advanced solid tumors and NSCLC
2024-512760-64-00Phase 2Authorised
- Sponsor
- Pierre Fabre Laboratories
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label trial of vert-002 in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Pierre Fabre Laboratories. Primary endpoints: Safety, Tolerability and 4 more. Planned start Feb 2025; status: authorised.
02
Drugs
vert-002
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-512760-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512760-64-00.